Ditching Delay: GH001’s Instant Impact on Depression

Connor Williams was shocked when the data came back for GH001. What could this mean for the future of treatment-resistant depression? Listen to his exclusive interview with Dr. Valcheva, the CEO of GH Research, to find out.PODCAST TEAMProducer: Devon LeaverEditor: Dominique GuerraFeaturing: Dr. Velichka (Villy) Valcheva MD, CEO of GH Research moderated by Connor Williams, Senior Research Analyst at RTW Investments.Don't forget to listen to part 1 of Connor’s discussion on treatment resistant depression and psychedelics with Stephanie Sirota, Managing Partner and Chief Business Officer at RTW Investments.FOLLOW USLove our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.CHAPTERS00:00 – Introduction01:09 – About GH Research04:20 – Becoming CEO of GH Research06:27 – The difference between GH001 and other psychedelics11:37 – The difficulties of developing a scheduled substance12:27 – Dealing with the stigma of psychedelics15:31 – What else can GH001 treat?17:26 – The future of GH Research20:53 – Outro and DisclaimerDISCLAIMERThis interview was given by Dr. Velichka (Villy) Valcheva MD, CEO of GH Research, and moderated by Connor Williams, Senior Research Analyst at RTW Investments. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent.